View DividendMYND Life Sciences 경영진경영진 기준 점검 2/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보 최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율n/a경영진 평균 재임 기간4.2yrs이사회 평균 재임 기간4.8yrs최근 경영진 업데이트공시 • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.공시 • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.공시 • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.공시 • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.공시 • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.공시 • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.모든 업데이트 보기Recent updates공시 • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.공시 • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.공시 • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.공시 • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.공시 • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.공시 • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.공시 • Oct 27MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc.MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc. on October 25, 2023. The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. It is anticipated the transaction will be completed in Q1 2024.공시 • Jan 10MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023.CEOMYND Life Sciences에는 CEO가 없거나 해당 데이터가 없습니다.리더십 팀이름직위재임 기간보수지분Wilfred JefferiesCo-Founder & Chief Science Officer5.3yrsCA$240.00k데이터 없음Lih-Ming TamCFO & Senior Controller4.1yrsCA$82.08k데이터 없음Chaahat SinghSenior Operations & Research Manager4.2yrs데이터 없음데이터 없음Iryna SaranchovaChief Clinical Officerno data데이터 없음데이터 없음더 보기4.2yrs평균 재임 기간경험이 풍부한 관리: MYND.F의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.2 년).이사회 구성원이름직위재임 기간보수지분Mark GeyerMember of Scientific Advisory Board4.8yrs데이터 없음데이터 없음Michael BrownsteinMember of Scientific Advisory Board4.8yrs데이터 없음데이터 없음John CampbellDirector5.3yrs데이터 없음데이터 없음Roslyn Ritchie-DerrienIndependent Director5.3yrs데이터 없음데이터 없음John TrowsdaleMember of Scientific Advisory Board4.8yrs데이터 없음데이터 없음Scott NicollIndependent Director4.4yrs데이터 없음데이터 없음Laurie BakkeIndependent Non Executive Director2.2yrs데이터 없음데이터 없음Lana HoogenboomDirector1.3yrs데이터 없음데이터 없음더 보기4.8yrs평균 재임 기간경험이 풍부한 이사회: MYND.F의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.8 년).View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/03/11 17:23종가2025/12/12 00:00수익2024/07/31연간 수익2023/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MYND Life Sciences Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.
공시 • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.
공시 • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.
공시 • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.
공시 • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
공시 • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
공시 • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.
공시 • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.
공시 • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.
공시 • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.
공시 • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
공시 • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
공시 • Oct 27MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc.MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc. on October 25, 2023. The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. It is anticipated the transaction will be completed in Q1 2024.
공시 • Jan 10MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023.